Blood-Based Biomarker Testing for Alzheimer’s Gets Formal Guidance
The Alzheimer's Association released its first clinical practice guideline on the use of blood-based biomarker tests.
The Alzheimer's Association released its first clinical practice guideline on the use of blood-based biomarker tests.
Blood-based biomarker tests are revolutionizing Alzheimer's diagnostic testing and management of Alzheimer’s disease.
Breath tests are increasingly being explored and implemented in clinical diagnosis, offering a non-invasive means to detect a variety of conditions like blood cancer, lung disease, lower respiratory tract infections, and gastroparesis.
In recent years, clinical laboratories have increasingly embraced automation to address challenges such as staffing shortages, budget constraints, and inefficiencies in manual processing.
AI-enhanced EEG technology is emerging as a promising tool for early detection of Alzheimer's disease, potentially facilitating prevention efforts before symptoms appear.